Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,148.00DKK
22 Jul 2016
Change (% chg)

kr.-9.00 (-0.78%)
Prev Close
kr.1,157.00
Open
kr.1,153.00
Day's High
kr.1,156.00
Day's Low
kr.1,140.00
Volume
208,426
Avg. Vol
437,475
52-wk High
kr.1,294.00
52-wk Low
kr.501.00

GEN.CO

Chart for GEN.CO

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.09
Market Cap(Mil.): kr.68,689.35
Shares Outstanding(Mil.): 59.83
Dividend: --
Yield (%): --

Financials

  GEN.CO Industry Sector
P/E (TTM): 128.28 39.80 37.05
EPS (TTM): 8.95 -- --
ROI: 17.50 -5.86 14.35
ROE: 17.50 -4.70 15.56

BRIEF-Genmab: negative opinion for use of Arzerra

* Committee for Medicinal Products for Human Use of European Medicines Agency issues negative opinion for the use of Arzerra for maintenance treatment of patients with relapsed chronic lymphocytic leukemia (CLL)

Jun 23 2016

NORDIC STOCKS - Factors to watch on June 2

The following stocks may be affected by newspaper reports and other factors on Thursday:

Jun 02 2016

BRIEF-Genmab announces phase III studies of sclerosis drug

* Says collaboration partner Novartis will start Phase III studies of ofatumumab in relapsing multiple sclerosis (MS)

Jun 02 2016

BRIEF-Genmab achieves $30 mln milestone in deal with Janssen

* Says milestone triggered by first commercial sale of Darzalex in Europe Source text for Eikon: Further company coverage: (Copenhagen newsroom)

May 30 2016

BRIEF-Genmab gets European conditional marketing authorization for Darzalex

* Says the European Commission (EC) has granted a conditional marketing authorization for first-in-class CD38 antibody Darzalex (daratumumab) for multiple Myeloma

May 23 2016

BRIEF-Genmab says first participants dosed in duobody study

* Says first participants dosed in clinical study with Duobody product

May 20 2016

BRIEF-Genmab to present daratumumab data at June conference

* Says data on daratumumab and ofatumumab will be presented at European Hematology Association's (EHA) congress in Copenhagen, June 9-12

May 19 2016

NORDIC STOCKS - Factors to watch on May 19

The following stocks may be affected by newspaper reports and other factors on Thursday:

May 19 2016

RPT-BRIEF-Genmab announces positive topline result in Phase III pollux study of Daratumumab in relapsed or refractory multiple Myeloma

* Genmab announces positive topline result in phase III pollux study of Daratumumab in relapsed or refractory multiple myeloma

May 19 2016

BRIEF-Genmab announces positive topline result in Phase III pollux study of Daratumumab in relapsed or refractory multiple Myeloma

* Genmab announces positive topline result in phase III pollux study of Daratumumab in relapsed or refractory multiple myeloma

May 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.